- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Points to Improved PFS in Prostate Cancer Patients on Statin Therapy
The study conducted by researchers at Dana-Farber Cancer Institute, and published in JAMA Oncology, found a siginificant increase in progression-free survival in men who initiated statin therapy along with androgen deprivation for their prostate cancer.
Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy (ADT) for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
In a study published online today by JAMA Oncology, the researchers report that men who had been taking statins since the start of androgen deprivation therapy went a median of 27.5 months before their disease began to worsen, compared to 17.4 months for men who didn't take statins. The trial involved 926 patients, 70% of whom had their disease progress during a 6-year period.
Read the complete news on EurekAlert!: http://bit.ly/1cap5Cy
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
